Define in Humans With Compensated CHF and Renal Dysfunction, the Modulating Action of Chronic AT1 Receptor Blockade in Addition to ACE Inhibition on Cardiorenal and Humoral Function
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 29 May 2019
At a glance
- Drugs Candesartan cilexetil (Primary)
- Indications Chronic heart failure; Renal impairment
- Focus Therapeutic Use
- 23 May 2019 Planned End Date changed from 30 Apr 2019 to 30 Dec 2019.
- 23 May 2019 Planned primary completion date changed from 31 Jan 2018 to 1 Jun 2019.
- 09 Apr 2018 Planned End Date changed from 30 Mar 2018 to 30 Apr 2019.